trivalent seasonal influenza vaccine

BIOLOGICAL3 trials

Sponsors

Biogen, Sinovac Biotech Co., Ltd, Institute of Vaccines and Medical Biologicals, Vietnam

Conditions

InfluenzaInfluenza, HumanRelapsing-Remitting Multiple Sclerosis

Phase 1

Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)

CompletedNCT02598089

Institute of Vaccines and Medical Biologicals, VietnamInfluenza, Human

Start: 2015-11-30End: 2016-02-29Updated: 2019-02-15

Phase 2

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

CompletedNCT01051349

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2010-03-31End: 2016-08-25Updated: 2018-11-09

Phase 4

The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

CompletedNCT02269852

Sinovac Biotech Co., LtdInfluenza

Start: 2013-12-31End: 2014-06-30Updated: 2015-09-21

Related Papers

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic Advances in Neurological Disorders2021-01-016 citations

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Journal of Neurology2020-05-2511 citations

Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults

Vaccine2016-08-3010 citations

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

2016-07-2635 citations

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.

2016-07-1314 citations

Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013–2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®

Human Vaccines & Immunotherapeutics2016-03-026 citations